Vegzelma

Celltrion is a leading South Korean biopharmaceutical company specializing in the development and manufacture of biosimilars and innovative biologics. The company is the developer of Vegzelma (bevacizumab-adcd), a biosimilar to Genentech's Avastin, which is approved for various oncology indications including metastatic colorectal cancer and non-small cell lung cancer. Celltrion's portfolio includes several other major biosimilars such as Remsima, Truxima, and Herzuma, which target autoimmune diseases and cancers. The company operates large-scale biologics manufacturing facilities in Incheon and maintains a vertically integrated business model that spans R&D, clinical trials, and global distribution. Celltrion is currently expanding its pipeline into new therapeutic areas like ophthalmology and is increasingly focusing on the development of novel biological therapies.